Aastrom Biosciences, Inc. Reports Operating Results for the Quarter and Six Months Ended June 30, 2012

Published: Aug 08, 2012

ANN ARBOR, Mich., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported operating results for the quarter and six months ended June 30, 2012.

Back to news